Peripheral blood-derived hematopoietic stem cells (PBHSC) can be utilized to reconstitute hematopoiesis in patients after high dose myeloablative chemotherapy. We have performed PBHSC reinfusion in 18 patients who have or had a history of tumor involving the bone marrow or a hypocellular bone marrow. The PBHSC were collected by continuous flow leukapheresis and subsequently cryopreserved. A median of 31.9 x 109 (range 18 x 109 - 67.2 x 109) mononuclear cells or a median of 4.85 x 108 mononuclear cells/kg (range 2.7 x 108 - 11.0 x 108) were collected. Fifteen patients had in vitro assays of granulocyte-monocyte colony-forming cells (CFU-GM) performed with a median of 2.7 x 104 (range 0-11.5 x 104) CFU-GM/kg. To date, of the 18 patients collected, all have undergone high dose chemotherapy and PBHSC reinfusion. For the evaluable patients, granulocyte recovery (>500 x 106/ml) has occurred in a median of 15 days and platelet recovery (>15 x 109/ml without transfusion support) has occurred in a median of 43 days. Four patients have had prolonged thrombocytopenia and still require platelet transfusion at 80+, 97+, 124+, and 270+ days. PBHSC collection is safe and effective for hematopoietic reconstitution after high dose chemotherapy in the majority of patients; however incomplete hematopoietic reconstitution has been observed in 4/18 evaluable patients. This procedure required further investigation.
|Original language||English (US)|
|Number of pages||5|
|Journal||Bone Marrow Transplantation|
|State||Published - 1990|
ASJC Scopus subject areas